ClinicalTrials.gg
Active, not recruitingNCT04874493Updated Jul 16, 2026

Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer

An observational study in Oropharyngeal Carcinoma, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
77
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center — 4 open to participants now, 10 under way, 1 of them phase 3. Oropharyngeal Neoplasms · M.D. Anderson Cancer Center.

Started
2021
the only one that year
Observational
9 of 26
1 open now
Registered
22nd of 26
by date

Among the 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center, this one is the only one that started in 2021, is one of 9 observational ones, and was the 22nd registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

4 of the 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This study examines patient reported outcomes post radiation therapy or chemoradiotherapy patient care in patients with oropharyngeal cancer. This study may help researchers learn about the symptoms that patients with oropharyngeal cancer have after completing radiation therapy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To provide evidence of clinically relevant symptoms for integrating into a user-friendly, automated pathway for real-time tracking and management of symptoms during post radiation therapy (RT)/chemoradiation (CRT) for oropharyngeal cancer (OPC).

OUTLINE:

Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.

03

Conditions studied

  • Oropharyngeal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with OPC who were seen for new patient evaluation at clinics and head and neck cancer (HNC) centers at MD Anderson Cancer Center

Eligibility criteria

Inclusion Criteria:

  • Patients who were seen for new patient evaluation at clinics and HNC centers at MD Anderson Cancer Center
  • Adult patients with OPC (> 18 years old) who have been enrolled under PA14-0947
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
77 participants (actual)

Groups and cohorts

  • Observational (questionnaire)

    Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.

    Other: Electronic Health Record Review · Other: Questionnaire Administration

Interventions

  • OtherElectronic Health Record Review

    Review of medical records

  • OtherQuestionnaire Administration

    Complete questionnaire

06

What researchers measure

Primary outcomes

  1. Scores of symptoms on the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) relevant to toxicities

    All symptom PRO items on MDASI-HN (MD Anderson Symptom Inventory - Head and Neck (MDASI) would be rated by patients on 0 -10 of severity scale, with 0 being no symptom, and 10 being symptom as bas as imagine.

    Time frame: From the end of radiation therapy (RT)/chemoradiotherapy (CRT) treatment to 2 months post-treatment

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Feb 2027, 70 months after the start.

Of 47 observational studies under Oropharyngeal Neoplasms, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 40. This study's planned 70 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2021
First posted
May 5, 2021
StartActual
Mar 10, 2021
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04874493
Responsible party
Sponsor
First posted
May 5, 2021
Start date
Mar 10, 2021
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Xin S Wang, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion